Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials

Figures & data

Table 1 Summary of studies using IL-17A antibodies as a treatment for the rheumatoid arthritis

Study (year)	Design	Number of patients	IL-17A antibody administered	Outcomes or end point	Jadad score
Genovese et al, 2010^Citation19	RCT	20 RA patients in part A and 77 patients in part B	LY2439821 (ixekizumab), from 0.06 mg/kg to 2.0 mg/kg intravenously one dose (part A) or five doses in total, one dose every 2 weeks	ACR and DAS28	4
Genovese et al, 2013^Citation20	RCT	237 patients with inadequate response to methotrexate	Secukinumab, 25 mg, 75 mg, 150 mg, 300 mg, and placebo	ACR20 and DAS28	5
Hueber et al, 2010^Citation21	RCT	52 RA patients	AIN457 at doses of 3–10 mg/kg, intravenously	ACR20	3
Martin et al, 2013^Citation23	RCT	52 RA patients	Brodalumab, 50 mg, 140 mg, or 210 mg subcutaneously, every 2 weeks for six doses per group, or 420 mg or 700 mg intravenously every 4 weeks for two doses per group	ACR20, ACR50, and ACR70	4
Patel et al, 2013^Citation22	RCT	52 RA patients for short time and 237 RA patients for long time	10 mg/kg secukinumab short time (4 weeks); 25–300 mg for longer time (16 weeks)	ACR20	5

Abbreviations: ACR, American College of Rheumatology; DAS, Disease Activity Score; IL, interleukin; RA, rheumatoid arthritis; RCT, randomized controlled trial.

Figure 1 Flow diagram for study selection.

Abbreviation: RCT, randomized controlled trial.

Figure 2 Forest plot of meta-analysis.

Notes: Figure demonstrates the improved scores of ACR20 after antibody treatment, as described in Genovese et al,^19,20 Hueber et al,²¹ Martin et al,²³ and Patel et al²² (A), and the increased levels of ACR50 (B) and ACR70 (C) in Genovese et al.^19,20 Meta-analysis was performed using a fixed model.
Abbreviations: ACR, American College of Rheumatology; CI, confidence interval; IL, interleukin; M–H, Mantel–Haenszel method.

Figure 3 Forest plot of studies selected for meta-analysis of adverse effects.

Note: Meta-analysis was performed in fixed model.
Abbreviations: CI, confidence interval; IL, interleukin; M–H, Mantel–Haenszel method.

Figure 4 Funnel plot of studies selected for meta-analysis of ACR20 (A), ACR50 (B), ACR70 (C), and adverse effects (D).

Abbreviations: ACR, American College of Rheumatology; OR, odds ratio; SE, standard error.

GenoveseMCVan den BoschFRobersonSALY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept studyArthritis Rheum201062492993920131262

 PubMed Web of Science ®Google Scholar

GenoveseMCDurezPRichardsHBEfficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyAnn Rheum Dis201372686386922730366

 PubMed Web of Science ®Google Scholar

HueberWPatelDDDryjaTRheumatoid Arthritis Study Group, Uveitis Study GroupEffects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitisSci Transl Med201025252ra72

 PubMed Web of Science ®Google Scholar

MartinDAChurchillMFlores-SuarezLA phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritisArthritis Res Ther2013155R16424286136

 PubMed Web of Science ®Google Scholar

PatelDDLeeDMKolbingerFAntoniCEffect of IL-17A blockade with secukinumab in autoimmune diseasesAnn Rheum Dis201372Suppl 2ii116ii12323253932

 PubMed Web of Science ®Google Scholar